EFPIA/CPIA Joint China/EU Pharmaceutical Industry Forum to Explore New Frontiers in Pharmaceutical Regulation

The fourth joint EFPIA and CPIA (Chinese Pharmaceutical Industry Association) China/EU Pharmaceutical Industry Forum will take place in Monday, 16 April 2018, in Basel, Switzerland.
Its aim is to showcase major developments in four key pharmaceutical policy areas: pharmaceuticals in the environment (PiE); coding and serialisation; compliance; and the uptake of the China Food and Drug Administration (CFDA) into the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).
Delegates will receive comprehensive information of the state of the pharmaceutical market in China and the pace of innovation in the sector. They will also hear the latest updates concerning China’s new pharmaceutical policies within the framework of the ICH, and industry’s support for the activities of the CFDA within this international body. There will be an opportunity to explore the Chinese Consensus Framework for the Ethical Collaboration in the Pharmaceutical and Medical Device Sectors as well as the evolution of environmental protections laid down by the Chinese pharmaceutical industry, with a particular focus on “Green Pharmaceuticals” in China.
Reflecting the positive developments in China – and with the clock ticking – delegates will be offered progress updates relating to the identification and authentication of medicines in Europe, in line with the requirements of the EU Falsified Medicines Directive. This will include a comprehensive overview of the FMD’s four-pillar approach, encompassing: safety features; active substances; reinforcing the distribution chain; and safeguarding against abuse in internet sales of pharmaceuticals. This will be accompanies by full explanations of the roles of the European Medicines Verification systems and the EU hub.
There will be a chance to gain further insight into the European pharmaceutical industry’s response to the European Commission’s consultation on pharmaceuticals in the environment. Delegates will also receive comprehensive information on the industry’s Eco-Pharmaco-Stewardship (EPS) lifecycle approach, the objective of which is to provide knowledge and data that enable assessments of the sustainability of pharmaceuticals.
Scienceindustries, the Swiss business association for the chemical, pharmaceutical and biotech industries, will provide insights into Swiss pharma self-regulation and outline its benefits for the local industry. Based on the IFPMA Code of Practice and the three EFPIA Codes, scienceindustries will explain how it has transformed pharma self-regulation by adopting: a Code of Conduct, encompassing integrity rules; and a Disclosure Code, focusing on cooperation and disclosure.
We look forward to receiving you at this interesting and informative event.

Media contact:
Andy Powrie-Smith, Executive Director, Communications & Partnerships